BioCentury | Feb 19, 2021
Finance

Canada’s Sagard tops off royalty fund at $725M, beating goal

...of the market. We’re not looking to compete directly with the larger established players, like Royalty Pharma,”...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...sciences companies that would benefit from non-dilutive investments.Keyoung pointed to existing U.S.-based firms such as Royalty Pharma plc...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...venture capital. Thomas was most recently CMO at Principia Biopharma, a unit of Sanofi (Euronext:SAN; NASDAQ:SNY). Royalty Pharma plc (NASDAQ:RPRX...
BioCentury | Dec 8, 2020
Deals

Dec. 7 Quick Takes: Sino pays $515M for Sinovac stake; plus BioCryst, Roivant, AbCellera, Syros, YZY, Maze

...Inc. (NASDAQ:BCRX) raised a total of $325 million via a $125 million upfront payment from Royalty Pharma plc...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...complete response letter from FDA requesting patch modifications, a new human factor study and additional CMC data.Royalty Pharma...
...a potential milestone payment of $75 million. The agreement eliminates obligations from a previous deal under which Royalty Pharma...
...KPT-330) Voclosporin ophthalmic solution garetosmab, REGN2477 ASP8374, PTZ-201 CARsgen Therapeutics Co. Ltd. Loyal Valley Capital Lilly Asia Ventures Shiyu Capital South China Venture Capital Royalty Pharma plc Vertex...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...Plains, N.J.-based Immunomedics entered a deal with Royalty Pharma plc...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...valuation of $1.4 billion. Biohaven in migraine royalty dealBiohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) will grant Royalty Pharma plc...
...ODT, rimegepant (BHV-3000, bms-927711) Zavegepant (BHV-3500) Qiagen N.V. Thermo Fisher Scientific Inc. Inhibrx Inc. Harmony Biosciences LLC Biohaven Pharmaceutical Holding Co. Ltd. Royalty Pharma plc Stanford...
BioCentury | Aug 8, 2020
Product Development

First oral SMA therapy will be delivered to patients’ homes, well placed for virtual launch

...Inc. (NASDAQ:PTCT), which sold rights to about 43% of its royalties from the therapy to Royalty Pharma plc...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...IPO (see “Legend’s NASDAQ Offering Pads 2020’s Lead Over Prior Years” ). Biopharma royalties buyer Royalty Pharma plc...
...Pharma Inc. Targets GM-CSF (CSF2) - Granulocyte macrophage colony-stimulating factor Robin Sawka, BioCentury Staff CureVac AG Legend Biotech Corp. Royalty Pharma plc NBE-Therapeutics...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...Royalty buys PTC royalty stream Royalty Pharma plc (NASDAQ:RPRX) is spending $650 million to acquire from PTC Therapeutics...
...in 2016-18. Targets HRH4 (H4) - Histamine H4 receptor BioCentury Staff adriforant (ZPL389) risdiplam (RG7916, RO7034067) Ziarco Group Ltd. Novartis AG Royalty Pharma plc PTC...
Items per page:
1 - 10 of 193
BioCentury | Feb 19, 2021
Finance

Canada’s Sagard tops off royalty fund at $725M, beating goal

...of the market. We’re not looking to compete directly with the larger established players, like Royalty Pharma,”...
BioCentury | Jan 4, 2021
Finance

With first royalty deal done, CBC’s R-Bridge fund aims for Asia-focused biotechs’ non-dilutive sweet spots

...sciences companies that would benefit from non-dilutive investments.Keyoung pointed to existing U.S.-based firms such as Royalty Pharma plc...
BioCentury | Dec 21, 2020
Management Tracks

CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more

...venture capital. Thomas was most recently CMO at Principia Biopharma, a unit of Sanofi (Euronext:SAN; NASDAQ:SNY). Royalty Pharma plc (NASDAQ:RPRX...
BioCentury | Dec 8, 2020
Deals

Dec. 7 Quick Takes: Sino pays $515M for Sinovac stake; plus BioCryst, Roivant, AbCellera, Syros, YZY, Maze

...Inc. (NASDAQ:BCRX) raised a total of $325 million via a $125 million upfront payment from Royalty Pharma plc...
BioCentury | Nov 3, 2020
Product Development

Nov. 2 Quick Takes: EMA reviewing filgotinib and DBV’s peanut allergy therapy; plus Royalty Pharma-CF Foundation, CARSgen, Karyopharm, Aurinia, Regeneron and Astellas

...complete response letter from FDA requesting patch modifications, a new human factor study and additional CMC data.Royalty Pharma...
...a potential milestone payment of $75 million. The agreement eliminates obligations from a previous deal under which Royalty Pharma...
...KPT-330) Voclosporin ophthalmic solution garetosmab, REGN2477 ASP8374, PTZ-201 CARsgen Therapeutics Co. Ltd. Loyal Valley Capital Lilly Asia Ventures Shiyu Capital South China Venture Capital Royalty Pharma plc Vertex...
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...Plains, N.J.-based Immunomedics entered a deal with Royalty Pharma plc...
BioCentury | Aug 14, 2020
Finance

Aug. 13 Quick Takes: Qiagen shareholders opt for independence; plus IPO terms from Inhibrx, Harmony and more from Biohaven-Royalty, Scioto, Bodyport, immunoSCAPE

...valuation of $1.4 billion. Biohaven in migraine royalty dealBiohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) will grant Royalty Pharma plc...
...ODT, rimegepant (BHV-3000, bms-927711) Zavegepant (BHV-3500) Qiagen N.V. Thermo Fisher Scientific Inc. Inhibrx Inc. Harmony Biosciences LLC Biohaven Pharmaceutical Holding Co. Ltd. Royalty Pharma plc Stanford...
BioCentury | Aug 8, 2020
Product Development

First oral SMA therapy will be delivered to patients’ homes, well placed for virtual launch

...Inc. (NASDAQ:PTCT), which sold rights to about 43% of its royalties from the therapy to Royalty Pharma plc...
BioCentury | Aug 5, 2020
Management Tracks

CureVac makes Haas’ CEO job permanent; plus Zhang now CEO of Legend and updates from Royalty, NBE, Black Diamond, VelosBio and more

...IPO (see “Legend’s NASDAQ Offering Pads 2020’s Lead Over Prior Years” ). Biopharma royalties buyer Royalty Pharma plc...
...Pharma Inc. Targets GM-CSF (CSF2) - Granulocyte macrophage colony-stimulating factor Robin Sawka, BioCentury Staff CureVac AG Legend Biotech Corp. Royalty Pharma plc NBE-Therapeutics...
BioCentury | Jul 22, 2020
Finance

July 21 Quick Takes: Royalty to reap risdiplam royalties; plus CureVac, Antengene, Citrine, Verona, Novartis, Amicus, Aslan, SAB, Gain

...Royalty buys PTC royalty stream Royalty Pharma plc (NASDAQ:RPRX) is spending $650 million to acquire from PTC Therapeutics...
...in 2016-18. Targets HRH4 (H4) - Histamine H4 receptor BioCentury Staff adriforant (ZPL389) risdiplam (RG7916, RO7034067) Ziarco Group Ltd. Novartis AG Royalty Pharma plc PTC...
Items per page:
1 - 10 of 193